

Op161218


1103326-0282

#17  
Nov  
11/4/99

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Cederberg et al.  
Serial No. : 08/945,425  
Filed : October 21, 1997  
For : ADMINISTRATION OF  
PHARMACEUTICALS  
Examiner : Desai, R.  
Group Art Unit : 1612

**RECEIVED**  
NOV 5 1999  
TECH CENTER 1600/2800

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231	
John M. Genova	32,224
Attorney Name	PTO Reg. No.
	11/1/99
Signature	Date of Signature

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 C.F.R. §1.97(c))**

Sir:

Applicant submits this communication in compliance with 37 C.F.R. §§1.56, 1.97 and  
1.98. Applicant requests consideration of the documents that are identified on the attached form  
PTO-1449. A copy of the documents are submitted concurrently with this Information Disclosure  
Statement.

11/04/1999 HKMARA 00000116 08945425

01 FC:126

240.00 OP

### **REMARKS**

By this communication, Applicants submit a copy and an English language translation of the publication Blum, A.L., "Perspektiven der Therapie mit Protonenpumpenblockern (PP-Blocker)", Gastroenterol (Suppl.1) 1995; 33:32-40). The Examiner's attention is particularly directed to Paragraph 3.3 of the publication.

In a previous Information Disclosure Statement, mailed April 7, 1999, Applicants identified International Publication No. WO 97/020202, published January 23, 1997. The underlying International Application No. PCT/EP96/02892 was filed July 2, 1996 and has a U.S. priority date of July 5, 1995. The U.S. priority application 08/498,386 has matured into U.S. Patent No. 5,945,124, issued August 31, 1999.

Copies of the documents listed on the PTO-1449 are enclosed.

### **TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the entry of the national stage as set forth in §1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last but before the mailing date of either:

(1) a final action under §1.113 or

(2) a notice of allowance under §1.311,

whichever occurs first.

**STATEMENT OR FEE**

Accompanying this Information Disclosure Statement is

A. ☐ a statement as specified in 37 C.F.R. §1.97 (e).

**OR**

B. ☒ the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$240.00).

**FEE PAYEMENT**

Applicant elects the option to pay the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement under §1.197(c) (\$240.00).

Fee due \$ 240.00

**METHOD OF PAYMENT OF FEE**

☒ Attached is a check in the amount of \$ 240.00.

☐ Charge Account No. 23-1703 in the amount of \$ \_\_\_\_\_. A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 23-1703.

Dated: November 1, 1999

Respectfully submitted,



John M. Genova

Reg. No. 32,224

Attorney for Applicant

White & Case LLP  
Patent Department  
1155 Avenue of the Americas  
New York, NY 10036-2787  
(212) 819-8200